Eli Lilly & Company (NYSE:LLY) ranks among the best set-it-and-forget-it stocks to buy. On June 27, UBS kept its Buy rating ...

Eli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website starting early August, the U.S. drugmaker said on Monday.

Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

CVS Caremark will stop covering Eli Lilly's Zepbound, a weight loss drug, due to insurance company changes. Patients are outraged and concerned.

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...

The company said the 12.5 milligrams and 15 mg doses of the drug will be available for US$499 per month on the website with shipments to self-paying patients.

Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...

While Zepbound leads today, the next potential rally may be sparked by Orforglipron, Eli Lilly's small-molecule oral GLP-1. Phase 3 obesity data is expected in the third quarter, with a launch ...